Biodexa Pharmaceuticals Plc BDRX
Regular-session close
After hours · Nov 19, 4:51 PM ET
- YTD
- -97.80%
- 1 year
- -98.71%
5D -0.47 (-19.42%)
- Market cap
- 1.05M
- Revenue (ttm)
- 83.00K
- EPS (ttm)
- 509.89
- Shares out
- 580.84K
- P/E ratio
- 0.00
- YTD return
- -97.80%
- 1-year return
- -98.71%
- 50-day average
- 5.20
- Volume
- 5.75K
- Avg volume
- 618.72K
- Open
- 2.04
- Previous close
- 2.04
- Day's range
- 1.95 – 2.04
- 52-week range
- 1.95 – 357.60
- Beta
- 1.44
- Price target
- 196.13 (+9731.2%)
Key statistics
- 200-day average
- 16.69
- Enterprise value
- 14.46B
- Price / sales
- 30.02
- Price / book
- 0.18
- Free cash flow
- -4.07M
- Total cash
- 5.05M
- Total debt
- 382.00K
- Return on equity
- -97.23%
- Short % of float
- 8.95%
Fundamental scorecard
6 of 25 checks passed on BDRX’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend No data
Statements to Jun 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 8, 2024 | Ladenburg Thalmann | init | — | Buy |
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- biodexapharma.com
News
Biodexa Pharma Announces Further Progress In Both Its Lead Programs; eRapa For Familial Adenomatous Polyposis And MTX240 Molecular Glue For Gastrointestinal Stromal Tumors
Biodexa provides R&D Update
Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
Interim results for the six months ended June 30, 2026
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
Result of General Meeting
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
Result of Annual General Meeting
Your note
Sign in to keep a note on BDRX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 1.53% | 10,218 | 43.83K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.19% | 1,303 | 5.59K | Sep 29, 2024 |
| Morgan Stanley | 0.09% | 573 | 2.46K | Sep 29, 2024 |
| Rhumbline Advisers | 0.04% | 242 | 1.04K | Sep 29, 2024 |
| Contravisory Investment Management, Inc. | 0.01% | 40 | 171 | Sep 29, 2024 |
| Gamma Investing LLC | 0.00% | 11 | 47 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 78 | 334 | Oct 30, 2024 |
